179 related articles for article (PubMed ID: 15765628)
1. Spotlight on estradiol and norgestimate as hormone replacement therapy in postmenopausal women.
Curran MP; Wagstaff AJ
Treat Endocrinol; 2002; 1(2):127-9. PubMed ID: 15765628
[TBL] [Abstract][Full Text] [Related]
2. Estradiol and norgestimate: a review of their combined use as hormone replacement therapy in postmenopausal women.
Curran MP; Wagstaff AJ
Drugs Aging; 2001; 18(11):863-85. PubMed ID: 11772126
[TBL] [Abstract][Full Text] [Related]
3. The effect of continuous oestradiol with intermittent norgestimate on bone mineral density and bone turnover in post-menopausal women.
Arrenbrecht S; Caubel P; Garnero P; Felsenberg D
Maturitas; 2004 Jul; 48(3):197-207. PubMed ID: 15207885
[TBL] [Abstract][Full Text] [Related]
4. Estradiol and dydrogesterone. A review of their combined use as hormone replacement therapy in postmenopausal women.
Foster RH; Balfour JA
Drugs Aging; 1997 Oct; 11(4):309-32. PubMed ID: 9342560
[TBL] [Abstract][Full Text] [Related]
5. A novel intermittent regimen of norgestimate to preserve the beneficial effects of 17beta-estradiol on lipid and lipoprotein profiles.
Lobo RA; Zacur HZ; Caubel P; Lane R
Am J Obstet Gynecol; 2000 Jan; 182(1 Pt 1):41-9. PubMed ID: 10649155
[TBL] [Abstract][Full Text] [Related]
6. Effects on serum lipid profiles of continuous 17beta-estradiol, intermittent norgestimate regimens versus continuous combined 17beta-estradiol/norethisterone acetate hormone replacement therapy.
Ylikorkala O; Lim P; Caubel P
Clin Ther; 2000 May; 22(5):622-36. PubMed ID: 10868559
[TBL] [Abstract][Full Text] [Related]
7. Intermittent progestin administration as part of hormone replacement therapy: long-term comparison between estradiol 1 mg combined with intermittent norgestimate and estradiol 2 mg combined with constant norethisterone acetate.
Ylikorkala O; Wahlström T; Caubel P; Lane R
Acta Obstet Gynecol Scand; 2002 Jul; 81(7):654-60. PubMed ID: 12190841
[TBL] [Abstract][Full Text] [Related]
8. Efficacy and safety of a constant-estrogen, pulsed-progestin regimen in hormone replacement therapy.
Sulak PJ; Caubel P; Lane R
Int J Fertil Womens Med; 1999; 44(6):286-96. PubMed ID: 10617250
[TBL] [Abstract][Full Text] [Related]
9. Constant estrogen, intermittent progestogen vs. continuous combined hormone replacement therapy: tolerability and effect on vasomotor symptoms.
Rozenberg S; Caubel P; Lim PC
Int J Gynaecol Obstet; 2001 Mar; 72(3):235-43. PubMed ID: 11226444
[TBL] [Abstract][Full Text] [Related]
10. Effect of two oral contraceptives containing ethinyl estradiol and gestodene or norgestimate on different lipid and lipoprotein parameters.
Wiegratz I; Jung-Hoffmann C; Gross W; Kuhl H
Contraception; 1998 Aug; 58(2):83-91. PubMed ID: 9773262
[TBL] [Abstract][Full Text] [Related]
11. Effects of E2 and E2/norgestimate hormone therapy on elevated baseline lipids.
Langer RD; Friedman AJ
J Reprod Med; 2006 Aug; 51(8):610-6. PubMed ID: 16967629
[TBL] [Abstract][Full Text] [Related]
12. The acceptability of a small intrauterine progestogen-releasing system for continuous combined hormone therapy in early postmenopausal women.
Sturdee DW; Rantala ML; Colau JC; Zahradnik HP; Riphagen FE;
Climacteric; 2004 Dec; 7(4):404-11. PubMed ID: 15799612
[TBL] [Abstract][Full Text] [Related]
13. Effects of low-dose norethindrone acetate plus ethinyl estradiol (0.5 mg/2.5 microg) in women with postmenopausal symptoms: updated analysis of three randomized, controlled trials.
Rowan JP; Simon JA; Speroff L; Ellman H
Clin Ther; 2006 Jun; 28(6):921-32. PubMed ID: 16860174
[TBL] [Abstract][Full Text] [Related]
14. Comparison of continuous and sequential transdermal progestogen with sequential oral progestogen in postmenopausal women using continuous transdermal estrogen: vasomotor symptoms, bleeding patterns, and serum lipids.
Rozenberg S; Ylikorkala O; Arrenbrecht S
Int J Fertil Womens Med; 1997; 42 Suppl 2():376-87. PubMed ID: 9397385
[TBL] [Abstract][Full Text] [Related]
15. Intrauterine 10 microg and 20 microg levonorgestrel systems in postmenopausal women receiving oral oestrogen replacement therapy: clinical, endometrial and metabolic response.
Raudaskoski T; Tapanainen J; Tomás E; Luotola H; Pekonen F; Ronni-Sivula H; Timonen H; Riphagen F; Laatikainen T
BJOG; 2002 Feb; 109(2):136-44. PubMed ID: 11888095
[TBL] [Abstract][Full Text] [Related]
16. Prevention of postmenopausal bone loss using tibolone or conventional peroral or transdermal hormone replacement therapy with 17beta-estradiol and dydrogesterone.
Lippuner K; Haenggi W; Birkhaeuser MH; Casez JP; Jaeger P
J Bone Miner Res; 1997 May; 12(5):806-12. PubMed ID: 9144347
[TBL] [Abstract][Full Text] [Related]
17. Levonorgestrel and 17beta-estradiol given transdermally for the prevention of postmenopausal osteoporosis.
Warming L; Ravn P; Christiansen C
Maturitas; 2005 Feb; 50(2):78-85. PubMed ID: 15653003
[TBL] [Abstract][Full Text] [Related]
18. Effectiveness of norgestimate and ethinyl estradiol in treating moderate acne vulgaris.
Lucky AW; Henderson TA; Olson WH; Robisch DM; Lebwohl M; Swinyer LJ
J Am Acad Dermatol; 1997 Nov; 37(5 Pt 1):746-54. PubMed ID: 9366821
[TBL] [Abstract][Full Text] [Related]
19. A norgestimate-containing oral contraceptive: review of clinical studies.
Kafrissen ME
Am J Obstet Gynecol; 1992 Oct; 167(4 Pt 2):1196-202. PubMed ID: 1415446
[TBL] [Abstract][Full Text] [Related]
20. Effect of a unique constant-estrogen, pulsed-progestin hormone replacement therapy containing 17beta-estradiol and norgestimate on endometrial histology.
Corson SL; Richart RM; Caubel P; Lim P
Int J Fertil Womens Med; 1999; 44(6):279-85. PubMed ID: 10617249
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
